Increased neoangiogenesis has been reported in myelofibrosis with myeloid metaplasia (MMM). Thus we studied the effects of thalidomide, an antiangiogenic drug, in 12 MMM patients. Before treatment, all the cases showed a significantly increased micro-vessel density (MVD); in all eight tested cases bFGF and VEGF plasma levels were higher than controls. All patients presented disease progression in the last 3 months with standard therapy, regarding splenomegaly, anemia and/or thrombocytopenia and/or hyperleukocytosis. Thalidomide was administered at daily doses increasing from 100 to 600 mg. Eleven out of 12 patients were evaluable. No progression of disease was seen during the treatment in any case. In particular, spleen size decreased in 7/11 patients, anemia improved in 3/4 (two are now transfusion independent), thrombocytopenia in 2/2 and hyperleukocytosis in 2/5 patients. Side-effects were frequent, although not severe. After treatment, VEGF and bFGF plasma levels varied widely and in selected cases decreased. In particular, VEGF and/or bFGF decreased in 4/5 responders and in 1/3 non-responders. Moreover, MVD significantly decreased in all the responders evaluated after treatment. We conclude that thalidomide is a feasible therapy in MMM patients and looks promising at least to control the growth progression of disease.
Introduction
Myelofibrosis with myeloid metaplasia (MMM) is a chronic myeloproliferative disorder characterized by clonal trilineage proliferation (granulocytic, erythroid and megakaryocytic) and secondary bone marrow fibrosis and osteosclerosis. Both megakaryocytes and monocytes are currently considered as the source of several cytokines responsible for stromal reaction, augmenting fibroblast proliferation (PDGF and calmodulin), collagen synthesis (TGF␤) and osteogenesis (TGF␤ and bFGF). 1 Clinically, MMM patients present with anemia and progressively symptomatic organomegaly. Life expectancy is compromised, infections, thromboemorrhagic events, progressive cachexia and leukemic transformation being the principal causes of death. 1 Management of the disease includes cytotoxic drugs, such as hydroxyurea, to control leukocytosis, thrombocytosis and hepatosplenomegaly, androgens and corticosteroids, to reduce anemia, and splenectomy. Nevertheless, conventional treatments for MMM are actually palliative, not improving survival; in addition, the frequently advanced age at diagnosis precludes allogeneic stem cell transplantation, a possible curative approach for the majority of patients.
Angiogenesis plays a significant role in the neoplastic development, progression and metastatization; [2] [3] [4] increasing reports suggest a possible implication in hematological malignancies. [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] Thalidomide, an immunomodulatory agent, demonstrated antiangiogenic properties in experimental in vitro and in vivo models 21 with clinical efficacy in multiple myeloma. 22 Moreover, recent observations showed increased VEGF plasma levels as well as bone marrow angiogenesis in MMM patients, the latter being an independent prognostic factor. 23 In addition, preliminary data indicate a possible therapeutic role in MMM and myelodysplastic syndromes (MDS). Barosi et al 24 described 21 MMM cases treated with thalidomide. The response rate was 61.5% but toxicity was relevant. Raza et al treated 83 MDS patients with thalidomide, obtaining hematological improvements and transfusion independency in several cases. 25, 26 The exact mechanism of action of thalidomide in hematological malignancies is not yet completely understood and, in particular, it is not well known if an antiangiogenic effect is relevant and if angiogenesis parameters, such as the micro-vessel density (MVD) evaluated before treatment with thalidomide, can predict clinical response.
We treated 12 MMM patients with thalidomide, who were characterized by progressive disease despite conventional therapy, and investigated the clinical response as well as the variations in neoangiogenesis parameters.
Patients and methods

Patients
Twelve patients previously diagnosed with MMM (11 primary and one secondary to polycythemia vera) from a single Institution were enrolled between January and December 2000. The study was conducted according to the principles of the Good Clinical Practice, after informed consent.
All patients were diagnosed according to the Italian Consensus Conference Criteria for the diagnosis of MMM. 27 Median age was 63 years (range 52-77); the median time from diagnosis was 11 years. [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] Four patients presented a hemoglobin level less than 10 g/dl, two a PLT count less than 50 × 10 9 /l, four a WBC count more than 10 × 10 9 /l and two less than 4 × 10 9 /l, and all 12 a splenomegaly (mean value was 17.5 cm from costal margin, range 2-25 cm). Two patients had disease classifiable as 'high risk', three as 'intermediate risk' and seven as 'low risk' according to the Dupriez score. 28 Four patients required periodic red blood cell transfusions and one platelet transfusion. All had been previously treated with conventional drugs (hydroxyurea, vinblastine, androgens and/or corticosteroids), with progression of disease in the last 3 months. Patients characteristics are presented in Table 1a and b. 
Treatment schedule
Thalidomide was purchased from Penn Pharmaceuticals (Tredegar, UK) and Grunenthal (Stolberg, Germany) as 100 mg capsules. Thalidomide was administered orally at a starting dose of 100 mg/day. The dose was then increased every 2 weeks by 100 mg/day up to 600 mg/day, in one or two daily doses if the dose was less than 400 mg or more than 300 mg, respectively. After 6 weeks of therapy, the study was considered completed; however, treatment was prolonged in responders until well tolerated. In particular, treatment was stopped after 6 weeks in the case of progression of disease, otherwise it was kept on at the maximum tolerated dose. After 4 months of therapy at this dose, we administered a maintenance dose of 100 mg/day, in order to reduce toxicity. 
Evaluation of response
Clinical and laboratory information was obtained at diagnosis and during the clinical course. Clinical response was evaluated after 6 weeks of treatment and then monthly. The criteria for evaluation are shown in Table 2 . Briefly, after 6 weeks of therapy, three groups of responses were considered: major response, minor response and stable disease. Patients were considered as major or minor responders if anemia (Hb Ͻ10 g/dl) improved at least 1 g/dl and/or thrombocytopenia (PLT Ͻ50 × 10 9 /l) improved at least twice or became Ͼ60 × 10 9 /l and/or hyperleukocytosis (WBC Ͼ15 × 10 9 /l) decreased to 10 × 10 9 /l and/or splenomegaly decreased at least 2 cm at the maximum diameter. Transfusion independence and improvements in other clinical parameters were also considered as responses.
If the above criteria were not satisfied, but there was no evidence of progression, disease was classified as stable. All the cases not fulfilling the criteria adopted to define responses and stable disease were considered as failures and treatment was discontinued.
Bone marrow analysis
A bone marrow biopsy was performed in all patients before treatment; all marrows were reviewed by two of the authors to confirm the accuracy of the diagnosis and assess the pathological stage 29 and the micro-vessel density (MVD). Bone marrow biopsy was prepared from paraffin-embedded blocks. Marrows were stained with hematoxylin and eosin in standard fashion. In order to evaluate endothelial cells, immunostains were adopted; although the antibody to CD34-stained myeloid progenitors, CD34 has been confirmed to be a useful antigen for assessing intratumor angiogenesis, as for other malignancies. 30 Two separate methods were used to estimate MVD. In the first method, visual micro-vessel grading, the slides were visu- The second method, visual count, involved counting of micro-vessels according to previously described methods. 23, 31 In performing this visual count, each of the slides was first scanned at × 100 magnification, and three areas with abundant micro-vessels were chosen and defined as 'hot spots'. The number of micro-vessels in each of these hot spots was then determined at × 400 magnification. The final MVD number (micro-vessels for high-power (× 400) field) was assigned by taking the average of the three separate visual counts. During the count process, large vessels and vessels in periosteum or bone and open sinusoids were excluded. Areas of staining with no discrete breaks were counted as single vessels and the presence of a lumen was not required.
Twenty bone marrow samples without tumor evidence were studied as controls.
Serological analysis
The measurement of the concentration of fibroblast growth factor basic (FGF basic) was evaluated in plasma samples from eight patients with ELISA kit (immunoassay kits; R&D Systems, Milan, Italy).
Briefly, standards and samples were pipetted into the wells containing a monoclonal antibody specific for FGF. After washing, an enzyme-linked polyclonal antibody specific for FGF was added to the wells. Then, a substrate solution was added to the wells and the color development in proportion to the amount of FGF bound was stopped with a stop solution. The intensity of the color was measured to the absorbance of 450-600 nm with a Labysystem microwell reader (Dasit).
The same method was adopted in order to measure VEGF plasma level in seven patients. In this case, monoclonal and polyclonal antibodies specific for VEGF were used.
Plasma samples from 20 normal controls were tested for both VEGF and bFGF.
Results
Treatment toxicity
Side-effects were frequent, although not severe in the majority of cases (grade I-III according to WHO classification) ( Table  3) . Only one patient reached the maximum planned dose of 600 mg/day; the other 10 required a dose reduction because of toxicity (seven for somnolence/lethargy, two for dizziness, and one for peripheral neuropathy). One patient dropped out the study after 2 weeks because of deep venous thrombosis, when taking 100 mg/day. Three patients were considered off the study, after 6, 6 and 16 weeks, for neurotoxicity (peripheral neuropathy in one case and dizziness in the other two); two dropped out of the study for personal reasons after 6 and 20 weeks, respectively; two stopped therapy for somnolence/lethargy. Previously reported myeloproliferative reactions were not observed in any case. 32 Currently, three patients are still on treatment with the maintenance dose of 100 mg/day, without affecting their life quality.
Istopathological findings and micro-vessel density assessment
Diagnosis of MMM has been confirmed in all the patients considered; two cases have been classified as stage II, 10 as stage III-IV. 29 MVD was clearly increased if compared to normal controls (Table 4) . Results from the two methods of evaluating angiogenesis adopted were absolutely comparable. Moreover, there was a very high inter-observer consensus with more than 95% agreement between reviewers. Mean MVD was 47 microvessels/field × 400 (median 37/field × 400) in patient marrow, while it was 7.2 micro-vessels/field × 400 (median 8/field × 400) in the controls. The difference was also confirmed with semiquantitative analysis; in fact, 20/20 controls showed a MVG 1, while patients presented a MGV 3 in six cases, a MGV 4 in five and a MGV 2 in one. No patient had a normal vessel count. Interestingly, we noted a significant difference in MVD between responder and non-responder patients (68 micro-vessels/field × 400 vs 36/field × 400).
In 3 /4 patients, defined as major responders, we performed a bone marrow biopsy at the time of response assessment; interestingly, we observed a clear reduction of MVD in all three cases (33 vs 16, 61 vs 43 and 71 vs 23 microvessels/field × 400).
Laboratory findings
VEGF and bFGF plasma levels were higher than controls in all cases before therapy. After treatment they varied widely and in selected cases decreased. In particular, 3/7 patients presented a VEGF reduction; all these three patients obtained a concurrent clinical response. In contrast, no patient, classified as a non-responder, showed a VEGF reduction. Moreover, in 4/8 cases we observed lower bFGF levels after thalidomide administration; in particular, 5/8 were classified as responders and 3/5 also showed a serological response, whereas 3/8 were not responders and only 1/3 obtained a cytokine reduction. All in all, eight patients were tested and 15 dosages were evaluable for VEGF or bFGF. Seven out of 15 presented lower VEGF and/or bFGF levels after therapy; interestingly, dosage 
Treatment response
Eleven out of 12 patients were evaluable for clinical response, one having a too short follow-up, less than 6 weeks. No progression of disease was observed in any patients, regarding anemia, thrombocytopenia, hyperleukocytosis, splenomegaly, leukemic evolution or other. Four out of 11 patients experienced a major response, one satisfying clinical criteria, two for peripheral blood and one improving both features; three patients showed a minor response, regarding clinical or laboratory parameters. In particular, two patients presented a spleen size reduction more than 25% (1 Ͼ50%) and five less than 25%. In three cases we observed an improvement of Hb level Ͼ2 g/dl, two becoming transfusion independent. Improvement of WBC counts, according to the established criteria, was seen in two cases. Two patients experienced a clinical response regarding thrombocytopenia; one of them improved platelet count from 5 × 10 9 /l up to 70 × 10 9 /l, obtaining transfusion independence, but dropped out of the study because of dizziness. All in all, seven patients were considered as responders; in four cases we observed stable disease. Interestingly, one patient showed stable disease during treatment, but presented a rapid increase in spleen size when therapy was suspended, because of peripheral neuropathy. We observed two delayed responses, with improvements of splenomegaly some weeks after withdrawal from therapy, such as described for myelodysplastic syndromes. 33 The median time to reach the maximum response was 4 weeks (range 2-18 weeks). All the observed responses were stable, not being lost during follow-up. Three patients are still on therapy at low doses (100 mg/day) in order to limit adverse effects; in all these cases the clinical benefits were maintained, but no conclusions can be assessed concerning the efficacy of low doses of thalidomide as reported in MM. 34 Results are summarized in Table 5 . MVD, micro-vessel density; MVG, micro-vessel grading. 
Discussion
We found that thalidomide has either biological and clinical effects in MMM patients. No progression of disease was observed during treatment, and seven out of 11 patients (64%) showed an improvement in at least one symptom. Recently, Barosi et al 24 described 21 (13 evaluable) MMM cases treated with thalidomide on a similar schedule; in their report the response rate was 61.5% with regard to improvements of anemia and/or thrombocytopenia and/or leukocytosis and/or reduction of spleen volume. Toxicity was relevant and 19/23 patients discontinued therapy before the planned 6 months. Our experience seems to confirm these data concerning both the incidence of effectiveness and side-effects. In our series, 7/11 patients showed a reduction of splenomegaly, in one case more than 50%; three cases presented an improvement in Hb level and two acquired transfusion independence; two patients showed a reduction of leukocytosis and two an improvement in thrombocytopenia (one obtaining transfusion independence); in particular, four patients experienced a major response: patients 2 and 5 obtaining a surprising response, with blood count normalization (one previously being transfusion dependent) and spleen size reduction; patient 1 improving Hb level and obtaining transfusion independence; patient 3 reducing spleen size of 25%. All the responders maintain their condition at the time of writing, with a median follow-up of 10 months. We believe these results are promising, especially considering that all patients had progressive disease when enrolled on the trial. Moreover, we obtained interesting information about MVD and surrogate parameters of angiogenesis, such as plasmatic levels of bFGF and VEGF. In fact, we observed increased MVD in all cases with respect to controls, as previously reported and, for the first time to the best of our knowledge, we found that patients with higher MVD before treatment could present a better clinical response to thalidomide.
No conclusions can be assessed with regard to the mechanism of action of thalidomide in this setting. In fact, it is an immunomodulatory and antiangiogenic agent with several properties able to explain the efficacy in MMM. This drug has shown antiangiogenic activity, inhibiting VEGF and bFGF pathways in a rabbit cornea micro-pocket assay and in a murine model of corneal vascularization. 21 It has also been shown to alter the expression of adhesion molecules 35 and various cytokynes as TNF␣ and IL-10. 36, 37 Moreover, it can Leukemia interact with Th1 and Th2 cells and directly stimulates T cytotoxic response. 38, 39 The reduction of angiogenic factors during treatment in selected cases, especially in responder patients, seems to suggest that antiangiogenic activity may play a significant role. In fact, it is not worth noting that 6/7 patients showing a reduction in VEGF and/or bFGF plasma level also obtained a clinical improvement. Despite this, other patients presented a reduction of their symptoms without any relevant serological change.
Interestingly, in two cases we observed a late response, both patients presenting a reduction in spleen size 4 and 10 weeks, respectively, after treatment discontinuation. All these findings suggest that anti-tumour action of thalidomide in MMM should depend on more than one mechanism.
Adverse effects are frequent, rarely severe, but often affect the patients' quality of life. In our experience, 7/12 patients discontinued treatment for toxicity; a dose reduction seems to reduce adverse events, although not completely and not in all cases. Other studies suggest the efficacy of low doses of thalidomide with minimal adverse events; 34 in our experience, a dose reduction seems feasible at least prolonging treatment in order to maintain clinical responses without relevant toxicity.
We conclude that thalidomide is effective in MMM, even in high risk patients refractory to conventional approach. We are now evaluating the biological effects of thalidomide in an in vitro assay, in order to better understand its mechanisms of action and further testing the efficacy of low-dose thalidomide in a clinical trial.
